Blog

Kohei Shitara: P2 results of futibatinib for FGFR2-amplified gastric cancer

Kohei Shitara/X

Feb 1, 2025, 07:13

Kohei Shitara: P2 results of futibatinib for FGFR2-amplified gastric cancer

Kohei Shitara, Medical Oncologist at National Cancer Center Hospital East, Japan, shared an article on X he and his colleagues authored:

“Pleased to share P2 results of futibatinib for FGFR2-amplified gastric cancer: ORR 17.9%. Shows some activity but underscores need for better options. Eagerly awaiting P3 chemo + bemarituzumab data.”

Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications

Authors: Taroh Satoh et al.

cancer Hidekazu Hirano Jaffer Ajani Jill Kremer Joon Oh Park Kazunori Honda Keun-Wook Lee Kohei shitara Lucia Nogova Mark Mina Mei Liu Min-Hee Ryu Nanae Hangai OncoDaily Oncology Philippe Barthélémy Sun Young Rha Taroh Satoh Toshihiko Doi

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment

Oncologist Near Me - Hagop Kantarjian: A Legend in Leukemia Research and Treatment

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Best of ASCOGI25

Egypt Cancer Society (ECS) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care